Identification of the MRTFA/SRF pathway as a critical regulator of quiescence and chemotherapy resistance in cancer
Cancer Letters · 2026
DOI: 10.1016/j.canlet.2026.218435 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2026. Verfasst von Santiago Panesso-Gómez und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Magee-Womens Research Institute, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: panessos@upmc…. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Trans-Activators, Serum Response Factor, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Medical Center, University of Pittsburgh, University of Pittsburgh.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Chemoresistance is a major cause of cancer deaths. One understudied mechanism of chemoresistance is quiescence. We used single-cell culture to identify and isolate patient-derived proliferating and quiescent ovarian cancer cells (qOvCa). RNA-seq analysis indicated that hundreds of genes that are differentially expressed in qOvCa cells are transcriptional targets of the Myocardin-Related Transcription Factor-A/Serum Response Factor (MRTFA/SRF) pathway, and both genetic disruption and pharmacologic inhibition of MRTFA/SRF interaction (with the inhibitor CCG257081) induced quiescence across multiple cancer types. MRTFA/SRF inhibition-mediated quiescence is p27/Kip1 dependent and associated with a downregulation of cell cycle regulators, NCL, MYH9, and alterations in the proteasome. We show that the MRTFA/SRF axis plays a dual role in chemotherapy resistance, with both pathway inhibition and activation contributing to chemotherapy resistance in vitro and in patient samples. CCG081 treatment results in a proteasome-dependent downregulation of the stem-cell marker CD133. Suggesting a critical role for the proteasome in quiescent cells, CCG081 therapy sensitized OvCa cells to proteasome inhibitors. In vivo, we found that CCG257081 therapy could be used to induce tumor growth-arrest and delay disease growth to improve overall survival. Moreover, we found that dual therapy with CCG081 and proteasome inhibition further improved outcomes, leading to undetectable tumors in ∼20% of mice. Together, these data suggest that the MRTFA/SRF pathway is a critical regulator of quiescence in cancer and a potential therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine and Magee-Womens Research Institute, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: panessos@upmc.edu.
- Department of Internal Medicine and Magee-Womens Research Institute, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: acol9471@alumni.sydney.edu.au.
- Department of Internal Medicine and Magee-Womens Research Institute, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: arrigoa@upmc.edu.
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: robertsa12@upmc.edu.
- Department of Internal Medicine and Magee-Womens Research Institute, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: bellom2@mwri.magee.edu.
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: Alyssa.wield@gmail.com.
Förderung
- NCI NIH HHS
- Medical Center, University of Pittsburgh
- University of Pittsburgh
- NIH
Zitieren
APA
Panesso-Gómez, S., Cole, A. J., Arrigo, A., Roberts, A., Bello, M., Wield, A., Anyaeche, V. I., McGonigal, S., Hijazi, A., Shah, J., Jiang, Q., Ebai, T., Sharrow, A. C., Tseng, G., Yoon, E., Brown, D. D., Clark, A. M., Larsen, S. D., Eder, I., …, & Buckanovich, R. J. (2026). Identification of the MRTFA/SRF pathway as a critical regulator of quiescence and chemotherapy resistance in cancer. Cancer Letters. https://doi.org/10.1016/j.canlet.2026.218435
Vancouver
Panesso-Gómez S, Cole AJ, Arrigo A, Roberts A, Bello M, Wield A, et al. Identification of the MRTFA/SRF pathway as a critical regulator of quiescence and chemotherapy resistance in cancer. Cancer Letters. 2026. doi:10.1016/j.canlet.2026.218435
BibTeX
@article{PanessoGmez2026,
author = {Panesso-Gómez, Santiago and Cole, Alexander J and Arrigo, Austin and Roberts, Alex and Bello, Maya and Wield, Alyssa and Anyaeche, Vivian I and McGonigal, Stacy and Hijazi, Amjad and Shah, Jaynish and Jiang, Qi and Ebai, Tonge and Sharrow, Allison C and Tseng, George and Yoon, Euisik and Brown, Daniel D and Clark, Amanda M and Larsen, Scott D and Eder, Ian and Gau, David and Roy, Partha and Tran, Lam and Jiang, Hui and Sannino, Sara and Goeckler-Fried, Jen and Choi, Yehyun and Brodsky, Jeffrey L and Osmanbeyoglu, Hatice and Ma, Xiaojun and Dahl, Kris N and McAuliffe, Priscilla F and Lee, Adrian V and Buckanovich, Ronald J},
title = {Identification of the MRTFA/SRF pathway as a critical regulator of quiescence and chemotherapy resistance in cancer},
journal = {Cancer Letters},
year = {2026},
doi = {10.1016/j.canlet.2026.218435}
}
EUVIMED